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DITORIAL
valuation  of  varicella  vaccine  effectiveness  as public
ealth tool for increasing  scientific  evidence  and
mproving vaccination  programs,
valiação  da  eficácia  da  vacina  contra  varicela  como  ferramenta  de  saúde
ública  para  aumentar  as  evidências  científicas  e  melhorar  os  programas  de
acinação
rancesco Vitale ∗, Emanuele Amodio










aricella  zoster  virus  (VZV)  is  a  ubiquitous  human  herpes
irus  that  is  spread  worldwide  and  causes  two  distinct
iseases.  These  latter  are  primary  varicella  infection  and
erpes  zoster,  a  vesicular  dermatomal  rash  that  results  from
eactivation  of  the  latent  virus.
Varicella  infection  is  usually  a  mild  self-limiting  illness,
haracterized  by  a  generalized  vesicular  rash  with  fever  and
alaise.  Complications  affect  around  2%--4%  of  cases  and,
n  developed  countries,  hospitalization  rates  are  approxi-
ately  two  to  three  per  1000  cases  among  healthy  children
nd  eight  per  1000  cases  among  adults,  determining  about
wo  to  three  deaths  per  100,000  cases.1,2 Complications
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ith  immune  deficiencies  and  pregnant  women,  but  can  also
ccur  among  previously  healthy  people.2
Before  the  introduction  of  the  vaccine,  varicella  was
ndemic  in  the  world,  with  an  annual  incidence  correspond-
ng  approximately  to  the  birth  cohort  of  each  country.  The
ntroduction  of  varicella  vaccine  has  significantly  changed
he  epidemiology  of  varicella.  The  vaccine  was  firstly  pro-
uced  in  Japan  in  the  1970s  but  it  was  introduced  in
ost  western  countries,  including  Germany,  Sweden,  Korea,
he  United  States,  and  Italy  in  late  1980s  and  1990s.3
 combined  measles-mumps-rubella-varicella  (MMRV)  live-
ttenuated  vaccine  has  been  also  developed  and  licensed
n  the  basis  of  non-inferior  immunogenicity  of  the  antigenic
omponents  compared  with  simultaneous  administration  of
MR  and  varicella  vaccines.4,5 MMRV  has  been  used  to  enable
ore  streamlined  integration  with  existing  childhood  vacci-
ation  schedules  in  order  to  increase  vaccination  coverage.
everal  efficacy  trials  documented  that  the  vaccine  was
afe  and  gave  a  high  degree  of  protection  against  vari-
ella  and,  for  this  reason,  the  World  Health  Organization
WHO)  recommends  that  countries  in  which  varicella  has






















































Varicella  vaccine  effectiveness  as  public  health  tool  
an  important  burden  of  disease  should  consider  introducing
varicella  vaccine  into  the  routine  childhood  immunization
schedule,  with  the  first  dose  given  at  12--18  months  of  age.6
A  recently  published  post-licensure  evaluation  of  vaccine
effectiveness  (VE)  analyzed  42  articles  published  between
1995  and  2014  and  found  that  for  one  dose,  VE  was  81%
(95%  CI:  78%--84%)  against  all  varicella  infections,  98%  (95%
CI:  97%--99%)  against  moderate/severe  varicella,  and  100%
for  prevention  of  severe  disease.7 The  pooled  two-dose  VE
against  all  varicella  diseases  was  92%  (95%  CI:  88%--95%),
with  no  significant  differences  between  VE  and  vaccine  type
or  study  design.  However,  it  is  recognized  that  there  is
a  need  for  further  studies  that  assess  and  monitor  vari-
cella  vaccination  introduction  in  different  areas  of  the  world
according  to  their  different  epidemiologic  scenarios.
According  to  this  mandate,  the  study  carried  out  by
Ribeiro  et  al.  and  published  in  this  issue  of  Jornal  de
Pediatria  enriches  the  current  international  literature  by
comparing  the  frequency  of  hospitalizations  and  deaths  due
to  varicella  before  (2010--2012)  and  after  (2014--2016)  the
vaccine’s  introduction  in  Brazil,  which  is  the  most  populated
country  in  South  America  and  the  fifth  most  populous  in  the
world,  with  more  than  200  million  people.8 In  particular,  the
authors  have  intended  to  analyze  the  effectiveness  of  the
MMRV  vaccine  introduction,  which  took  place  in  September
2013  for  infants  at  15  months.
Such  studies  as  this  have  an  essential  role  in  increasing
evidence-based  public  health  practices  and  in  assessing  epi-
demiological  findings  that  could  be  of  interest  for  making
adjustments,  if  required,  to  vaccination  programs  from  a
national  point  of  view.  The  results  of  the  study  confirm  that
in  Brazil  varicella  accounted  for  a  high  burden  of  disease
that,  in  the  pre-vaccination  era  (2010--2012),  caused  hospi-
talization  rates  of  39.6/100,000  in  infants  aged  <1  year  and
19.6/100,000  in  children  aged  1--4  years,  and  mortality  rates
of  1.36/100,000  in  infants  aged  <1  year  and  0.68/100,000  in
children  aged  1--4  years,  respectively.  After  MMRV  vaccine
introduction,  significant  reductions  were  observed  in  both
hospitalization  rates  (−40%  in  infants  <1  year  and  −47%  in
children  1--4  years)  and  mortality  rates  (−57%  in  infants
<1  year  and  −49%  in  children  1--4  years).  These  results
are  strongly  encouraging  since  they  confirm  that  varicella
vaccination  is  associated  with  an  immediate  reduction  of
the  burden  of  the  disease,  evident  just  after  few  years
from  vaccine  introduction.  The  decreased  hospitalization
and  mortality  rates  should  be  also  considered  in  the  light  of
the  economic  and  societal  burden  sustained  by  all  varicella
cases,  of  which  they  represent  only  the  tip  of  the  iceberg.
However,  at  a  first  glance,  the  findings  from  Ribeiro
et  al.  could  suggest  relatively  moderate  vaccine  effective-
ness  and,  thus,  for  this  reason  they  need  to  be  adequately
contextualized.  In  a  recent  analysis,  our  research  group
found  that  in  Italy,  from  2003  to  2018,  varicella  vaccina-
tion  effectiveness  on  reducing  hospitalization  risk  can  be
of  higher  impact  as  well  as  −80.0%  in  the  <1  year  age
class  and  −86.7%  in  children  aged  1--5  years  (article  submit-
ted  for  publication).9,10 Similarly,  decreasing  hospitalization
rate  percentages  were  found  in  other  countries,  as  Germany
(−77.6%  in  children  <5  years)  or  Spain  (-83.5%  in  children  <5
years),  Australia  (−76.8%  in  children  1--4  years),  Canada  (-







For  improving  the  interpretation  of  these  data,  it  should
e  considered  that  among  the  different  factors  that  can
nfluence  vaccination  effectiveness,  a  main  role  is  played
y  vaccination  coverage  and  the  number  of  years  since  the
ntroduction  of  the  vaccination.16 The  higher  the  contribu-
ion  of  these  two  factors,  the  greater  the  positive  effects
n  the  general  populations’  health.  This  assumption  is  fur-
her  confirmed  by  considering  that  in  the  study  by  Ribeiro
t  al.  the  impact  of  vaccination  was  heterogeneous  across
he  country’s  macro  regions,  being  higher  in  the  regions
ith  higher  vaccination  coverage  as  well  as  South  region
VC  >  85%).  Nonetheless,  as  stated  by  the  authors,  the  short
ost-vaccination  period  studied  may  underestimate  the  indi-
ect  effect  provided  by  the  vaccination.  According  to  these
onsiderations,  in  Sicily  we  have  found  that  increasing  vari-
ella  vaccination  coverage  rates  (from  40%  in  2001  birth
ohort  to  85%  in  2010  birth  cohort)  were  significantly  corre-
ated  with  a  progressive  reduction  of  varicella  notifications
nd  hospitalization  rates.17
Notably,  Ribeiro  et  al.  found  a  significant  reduction  in
ospitalization  and  mortality  rates  among  children  aged
1  year  and  5--14  years  that,  in  our  opinion,  should  be  con-
idered  as  a  probable  consequence  of  herd  protection.  It  is
robable  that  with  time  the  strength  of  vaccine  effective-
ess  will  increase  among  5  to  14-year-old  children  since  a
rowing  percentage  of  these  will  belong  to  previously  vac-
inated  birth  cohorts.
There  is  a  third  important  factor  that  should  be  taken
nto  careful  consideration  when  evaluating  vaccine  effec-
iveness  studies,  which  is  the  validity  of  collected  data.
nder  diagnosis  and  underreporting  are  still  quite  frequent
n  all  countries  and,  particularly,  in  regions  where  access
o  health  services  can  be  still  precarious,  as  stated  by  the
uthors  for  some  areas  of  Brazil.  Moreover,  epidemiologi-
al  follow-up  of  Brazilian  vaccination  coverage  is  essential
o  ensure  reaching  and  sustaining  vaccine  coverage  ≥80%,
hich  is  the  critical  threshold  necessary  to  maintain  herd
mmunity  and  reduce  the  risk  to  shift  varicella  infection
o  older  ages,  with  an  increase  of  morbidity  and  mortality
espite  reduction  in  total  numbers  of  cases.  Further  stud-
es  investigating  the  reasons  for  low  vaccination  coverage
bserved  in  different  Brazilian  regions  could  be  the  need  for
valuating  possible  roles  played  by  anti-vaccine  movements
r  difficulties  in  vaccination  offer  by  the  national  health
ystem.
Moreover,  as  recommended  by  the  WHO,  assessing  aver-
ge  age  of  acquisition  of  varicella  infections  could  suggest
he  need  for  considering  alternative  vaccination  strategies
uch  as  vaccination  (or  catch  up)  of  adolescents  and  adults
ithout  evidence  of  varicella  immunity.6
Although  the  study  by  Ribeiro  et  al.  could  have  some
imitations,  mainly  related  to  the  retrospective  ecological
pproach,  the  reported  findings  strongly  confirm  that  in
razil  varicella  has  had  a significant  burden  in  terms  of  hospi-
alization  and  mortality  before  the  introduction  of  universal
ass  varicella  vaccination.  Moreover,  there  is  the  evidence
or  the  vaccine’s  effectiveness  in  significantly  reducing  this
urden  in  the  years  immediately  following  its  introduction.
n  the  coming  years,  these  data  will  need  to  be  confirmed
nd  monitored  in  order  to  avoid  a  possible  perverse  effect
ue  to  low  vaccination  coverage  with  increase  in  the  number
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